A Review of PI3K Inhibitors in B-Cell Malignancies.
J Adv Pract Oncol
; 10(7): 715-725, 2019.
Article
en En
| MEDLINE
| ID: mdl-33391855
ABSTRACT
The phosphoinositide 3-kinase (PI3K) pathway plays a primary role in cellular proliferation and metabolism. Inhibition of the PI3K pathway is an emerging area of drug development and cancer research. Idelalisib, copanlisib, and duvelisib are currently the only U.S. Food & Drug Administration-approved PI3K inhibitors available for use in hematologic malignancies. These PI3K inhibitors differ in their recommended indications, selectivity of PI3K isoforms, dosing, and potential toxicities. Several ongoing studies are aiming to expand the use of such drugs and identify unique combination regimens. This article discusses the current data supporting their place in therapy for B-cell malignancies, management of adverse events, and the clinical implications for advanced practitioners for the commercially available PI3K inhibitors.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
J Adv Pract Oncol
Año:
2019
Tipo del documento:
Article